Prime Medicine Inc

For the period ended Dec 31, 2024. Filed Feb 28, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 28, 2025

PRME$3.90-9.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive Loss F-

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

	Year Ended December 31,
(in thousands, except share and per share amounts)	2024	2023
Revenue:
Collaboration revenue — related party	$1,609	$—
Collaboration revenue	1,374	—
Total revenue	2,983	—
Operating expenses:
Research and development (1)	155,289	147,905
Settlement payment — related party	—	13,500
General and administrative	50,161	43,387
Total operating expenses	205,450	204,792
Loss from operations	(202,467)	(204,792)
Other income:
Interest income	3,522	2,811
Accretion (amortization) of investments	3,507	5,677
Change in fair value of short-term investment — related party	(485)	(2,382)
Other income, net	41	274
Total other income, net	6,585	6,380
Net loss before income taxes	(195,882)	(198,412)
Benefit from income taxes	—	279
Net loss attributable to common stockholders	$(195,882)	$(198,133)
Net loss per share attributable to common stockholders, basic and diluted	$(1.65)	$(2.18)
Weighted-average common shares outstanding, basic and diluted	118,600,381	90,969,327
Comprehensive loss:
Net loss	$(195,882)	$(198,133)
Change in unrealized loss on investments, net of tax	16	369
Comprehensive loss	$(195,866)	$(197,764)

(1)Includes related party amounts of $— million and $0.6 million for the years ended December 31, 2024 and 2023, respectively.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.